Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfusion and second malignancy

C D Ford1, J W Gillette, D L Handrahan

  • 1Tumor Registry, LDS Hospital, Salt Lake City, Utah.

Transfusion
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.

Transplant infectious disease : an official journal of the Transplantation Society·2016
Same author

The clinical impact of vancomycin-resistant Enterococcus colonization and bloodstream infection in patients undergoing autologous transplantation.

Transplant infectious disease : an official journal of the Transplantation Society·2015
Same author

Disseminated histoplasmosis in allogeneic bone marrow transplant: a diagnosis not to be missed.

Transplant infectious disease : an official journal of the Transplantation Society·2014
Same author

CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.

Bone marrow transplantation·2009
Same author

Effect of prior chemotherapy on hematopoietic stem cell mobilization.

Bone marrow transplantation·2004
Same author

An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors.

Transfusion·2003
Same journal

Spray dried plasma manufactured from apheresis and whole blood derived plasma.

Transfusion·2026
Same journal

Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

Transfusion·2026
Same journal

AABB survey on directed blood donation practices.

Transfusion·2026
Same journal

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
Same journal

A novel translation initiation codon single nucleotide variant of the SLC14A1 (c.2T>G) from a Chinese blood donor with Jk(a-b-) phenotype.

Transfusion·2026
Same journal

Size (and frequency) matter: Evaluating the best management practices for blood products with spotty demand.

Transfusion·2026
See all related articles

Perioperative blood transfusions did not increase the risk of developing a second cancer in patients previously treated for colon cancer. This study found no link between transfusion history and subsequent malignancy development.

Area of Science:

  • Oncology
  • Transfusion Medicine
  • Cancer Epidemiology

Background:

  • Perioperative blood transfusion is linked to immunosuppression and increased cancer recurrence.
  • The impact of perioperative transfusion on second malignancy risk remains unexplored.

Purpose of the Study:

  • To investigate the association between perioperative blood transfusion and the risk of developing a second malignancy in colon cancer survivors.

Main Methods:

  • A cohort of 1053 patients with prior colon cancer surgery was analyzed.
  • Patients' perioperative transfusion history was correlated with their second malignancy risk.

Main Results:

  • No statistically significant relationship was found between transfusion history and the likelihood of remaining cancer-free.

Related Experiment Videos

  • The probability of developing a second malignancy was not influenced by perioperative blood transfusions.

    • Conclusions:

    • Perioperative blood transfusion does not appear to elevate the overall risk of second malignancies.
    • An exception might exist for lung cancer, though further research is needed.